IBCSG 18-98 / BIG 1-98

  • Adjuvant therapy for postmenopausal patients with operable breast cancer who have estrogen receptor or progesteron receptor positive tumor. Tamoxifen vs. letrozole vs. tamoxifen followed by letrozole vs. letrozole followed by tamoxifen

  • Study Chair
    Prof. Beat Thürlimann - St. Gallen, Switzerland

    Statisticians
    Anita Giobbie-Hurder
    Dr. Zhuoxin Sun

    Director of the Data Management Center
    Holly Shaw


    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    March, 1998

    Date of Closure
    Core Protocol: May 13, 2003
    GS/SLP Substudy: February 7, 2003
    BMD Substudy: February 7, 2003
    New Bone Substudy: January 31, 2007
    Fingernail Pilot Substudy: July 31, 2007
    Cognitive Function Substudy: May 20, 2008

    Final Accrual
    Core Protocol: 8028 patients
    GS/SLP Substudy: 65 patients
    BMD Substudy: 39 patients
    New Bone Substudy: 458 patients
    Fingernail Pilot Substudy: 16 patients
    Cognitive Function Substudy: 135 patients

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login